anti-CD1a CAR-T cells

Anti-CD1a CAR-T cells is an investigational chimeric antigen receptor (CAR) T-cell therapy being developed by The Affiliated Hospital of Xuzhou Medical University for the treatment of relapsed or refractory acute T-lymphoblastic leukemia (T-ALL) and lymphoblastic lymphoma (LBL). The therapy involves genetically engineering T-cells to express a CAR that specifically targets CD1a, a transmembrane glycoprotein expressed in approximately 40% of T-ALL cases, particularly the cortical T-ALL subtype. Because CD1a is not expressed on mature peripheral blood T-cells, this approach avoids the issue of fratricide (CAR-T cells killing each other) during the manufacturing process. The mechanism of action involves direct immunologic cytotoxicity against CD1a-positive malignant cells, leading to the elimination of leukemic blasts.

Other names

anti-CD1a chimeric antigen receptor T-cellsanti-CD-1a chimeric antigen receptor T-cellsanti-CD 1a chimeric antigen receptor T-cellsCD1a CAR-TCD-1a CAR-TCD 1a CAR-Tanti-CD1a CAR-Tanti-CD-1a CAR-Tanti-CD 1a CAR-T